CytomX Therapeutics (CTMX) News Today $0.89 +0.02 (+2.30%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Equities Analysts Issue Forecasts for CTMX FY2024 EarningsNovember 15, 2024 | americanbankingnews.comResearch Analysts Set Expectations for CTMX FY2024 EarningsCytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) - Analysts at HC Wainwright raised their FY2024 earnings estimates for shares of CytomX Therapeutics in a report issued on Monday, November 11th. HC Wainwright analyst M. Kapoor now expects that the biotechnology company will post earnings perNovember 13, 2024 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Receives "Neutral" Rating from HC WainwrightHC Wainwright reaffirmed a "neutral" rating on shares of CytomX Therapeutics in a report on Monday.November 11, 2024 | marketbeat.comCytomX Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 10, 2024 | uk.finance.yahoo.comCytomX Therapeutics price target lowered to $3.25 from $3.50 at Piper SandlerNovember 9, 2024 | markets.businessinsider.comCytomX Therapeutics (NASDAQ:CTMX) Share Price Passes Below Fifty Day Moving Average - Here's WhyCytomX Therapeutics (NASDAQ:CTMX) Share Price Passes Below 50-Day Moving Average - Here's WhyNovember 9, 2024 | marketbeat.comQ3 2024 CytomX Therapeutics Inc Earnings CallNovember 8, 2024 | uk.finance.yahoo.comCytomX Therapeutics Reports Q3 Progress and GrowthNovember 8, 2024 | markets.businessinsider.comCytomX Therapeutics (CTMX) Receives a Buy from BarclaysNovember 8, 2024 | markets.businessinsider.comCytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | seekingalpha.comCytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...November 8, 2024 | finance.yahoo.comCytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 7, 2024 | globenewswire.comEarnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 2024 ResultNovember 6, 2024 | finance.yahoo.comCytomX Therapeutics (CTMX) Scheduled to Post Quarterly Earnings on ThursdayCytomX Therapeutics (NASDAQ:CTMX) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six analysts that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and three have given a buy recommendatiOctober 31, 2024 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 10.5% in SeptemberCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) was the recipient of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totalling 6,250,000 shares, a decrease of 10.5% from the September 15th total of 6,980,000 shares. Based on an average trading volume of 686,500 shares, the short-interest ratio is currently 9.1 days.October 17, 2024 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comH.C. Wainwright Sticks to Their Hold Rating for CytomX Therapeutics (CTMX)September 14, 2024 | markets.businessinsider.comCytomX Therapeutics' (CTMX) "Neutral" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "neutral" rating on shares of CytomX Therapeutics in a research report on Friday.September 13, 2024 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Moderate Buy" by AnalystsCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six research firms that are covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the company. ThSeptember 11, 2024 | marketbeat.comCytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid TumorsSeptember 9, 2024 | globenewswire.comInsider Selling: CytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sells 13,898 Shares of StockAugust 23, 2024 | insidertrades.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sean A. Mccarthy Sells 13,898 SharesCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) CEO Sean A. Mccarthy sold 13,898 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $1.23, for a total transaction of $17,094.54. Following the completion of the transaction, the chief executive officer now owns 657,851 shares in the company, valued at approximately $809,156.73. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.August 22, 2024 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reaffirmed a "neutral" rating on shares of CytomX Therapeutics in a report on Thursday.August 22, 2024 | marketbeat.comAssenagon Asset Management S.A. Acquires 833,825 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX)Assenagon Asset Management S.A. boosted its holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 206.0% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,238,499 shares of the biotechnology company's stAugust 22, 2024 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Consensus Rating of "Moderate Buy" by BrokeragesCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are presently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on theAugust 17, 2024 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Posts Earnings Results, Misses Estimates By $0.01 EPSCytomX Therapeutics (NASDAQ:CTMX - Get Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). CytomX Therapeutics had a net margin of 13.87% and a negative return on equity of 30.70%. The firm had revenue of $25.12 million during the quarter, compared to the consensus estimate of $21.79 million. During the same quarter in the prior year, the business earned ($0.02) earnings per share.August 11, 2024 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2024 Earnings Call TranscriptAugust 10, 2024 | insidermonkey.comCytomX Therapeutics, Inc. (CTMX) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | seekingalpha.comCytomX Therapeutics Inc.: CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 9, 2024 | finanznachrichten.deCytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 8, 2024 | globenewswire.comCytomX Therapeutics (CTMX) to Release Earnings on ThursdayCytomX Therapeutics (NASDAQ:CTMX) will be releasing earnings after the market closes on Thursday, August 8, Zacks reports.August 2, 2024 | marketbeat.comCytomX Therapeutics, Inc. (CTMX): The Best One-Dollar Stock to Buy Now?July 25, 2024 | msn.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Consensus Recommendation of "Moderate Buy" by AnalystsCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six ratings firms that are covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and three have assigned a buy recommJuly 23, 2024 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) is definitely on the radar of institutional investors who own 47% of the companyJuly 22, 2024 | finance.yahoo.comCytomX Therapeutics (NASDAQ:CTMX) Shares Cross Below Fifty Day Moving Average of $1.67CytomX Therapeutics (NASDAQ:CTMX) Share Price Passes Below 50-Day Moving Average of $1.67July 16, 2024 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Rating of "Moderate Buy" from BrokeragesCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has earned an average rating of "Moderate Buy" from the six analysts that are currently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rJune 28, 2024 | marketbeat.comCytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual ConferenceJune 18, 2024 | globenewswire.comCytomX Therapeutics (NASDAQ:CTMX) Cut to "Hold" at StockNews.comStockNews.com downgraded shares of CytomX Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday.June 17, 2024 | marketbeat.comCytomX Therapeutics Promotes Chris Ogden to Chief Financial OfficerJune 17, 2024 | globenewswire.comCytomX Therapeutics (NASDAQ:CTMX) Share Price Crosses Below Fifty Day Moving Average of $2.14CytomX Therapeutics (NASDAQ:CTMX) Shares Cross Below Fifty Day Moving Average of $2.14June 12, 2024 | marketbeat.comNo Memes, Ma’am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.May 29, 2024 | investorplace.comNo Memes, Ma'am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.May 29, 2024 | investorplace.comPiper Sandler Upgrades CytomX Therapeutics (CTMX)May 29, 2024 | msn.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Sees Large Growth in Short InterestCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw a large increase in short interest in the month of May. As of May 15th, there was short interest totalling 8,750,000 shares, an increase of 143.1% from the April 30th total of 3,600,000 shares. Based on an average daily trading volume, of 6,480,000 shares, the short-interest ratio is presently 1.4 days.May 28, 2024 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Rating Increased to Overweight at Piper SandlerPiper Sandler upgraded CytomX Therapeutics from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $2.25 to $3.50 in a research report on Tuesday.May 28, 2024 | marketbeat.comCytomX Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 22, 2024 | globenewswire.comCytomX Therapeutics Announces New Employment Inducement GrantsMay 16, 2024 | globenewswire.comCytomX Therapeutics Inc.May 11, 2024 | wsj.comStockNews.com Upgrades CytomX Therapeutics (NASDAQ:CTMX) to BuyStockNews.com upgraded shares of CytomX Therapeutics from a "hold" rating to a "buy" rating in a research report on Friday.May 11, 2024 | marketbeat.com Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address Buffett Dumps $982 Million in BofA Stock—What Does He Know? (Ad)Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention. Get your FREE, no-obligation Wealth Protection Guide now CTMX Media Mentions By Week CTMX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTMX News Sentiment▼0.600.49▲Average Medical News Sentiment CTMX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTMX Articles This Week▼12▲CTMX Articles Average Week Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DURECT News Today MEI Pharma News Today Immutep News Today Poseida Therapeutics News Today Lifecore Biomedical News Today Lyell Immunopharma News Today Atai Life Sciences News Today Atyr PHARMA News Today Mersana Therapeutics News Today Aurora Cannabis News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTMX) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
